PT - JOURNAL ARTICLE AU - Anna Abou-Raya AU - Suzan Abou-Raya AU - Tarek Khadrawi AU - Madihah Helmii TI - Effect of Low-dose Oral Prednisolone on Symptoms and Systemic Inflammation in Older Adults with Moderate to Severe Knee Osteoarthritis: A Randomized Placebo-controlled Trial AID - 10.3899/jrheum.130199 DP - 2013 Dec 01 TA - The Journal of Rheumatology PG - jrheum.130199 4099 - http://www.jrheum.org/content/early/2013/11/25/jrheum.130199.short 4100 - http://www.jrheum.org/content/early/2013/11/25/jrheum.130199.full AB - Objective To investigate the efficacy of 6 weeks of daily low-dose oral prednisolone in improving pain, mobility, and systemic low-grade inflammation in the short term and whether the effect would be sustained at 12 weeks in older adults with moderate to severe knee osteoarthritis (OA). Methods A total of 125 patients with primary knee OA were randomized 1:1; 63 received 7.5 mg/day of prednisolone and 62 received placebo for 6 weeks. Outcome measures included pain reduction and improvement in function scores and systemic inflammation markers. Pain was assessed using the visual analog pain scale (0–100 mm). Secondary outcome measures included the Western Ontario and McMaster Universities Osteoarthritis Index scores, patient global assessment (PGA) of the severity of knee OA, and 6-min walk distance (6MWD). Serum levels of interleukin 1 (IL-1), IL-6, tumor necrosis factor (TNF)-α, and high-sensitivity C-reactive protein (hsCRP) were measured. Results There was a clinically relevant reduction in the intervention group compared to the placebo group for knee pain, physical function, PGA, and 6MWD at 6 weeks. The mean difference between treatment arms (95% CI) was 10.9 (4.8–18.0), p > 0.001; 9.5 (3.7–15.4), p > 0.05; 15.7 (5.3–26.1), p > 0.001; and 86.9 (29.8–144.1), p > 0.05, respectively. Further, there was a clinically relevant reduction in the serum levels of IL-1, IL-6, TNF-α, and hsCRP at 6 weeks in the intervention group when compared to the placebo group. These differences remained significant at 12 weeks. The Outcome Measures in Rheumatology Clinical Trials-Osteoarthritis Research Society International responder rate was 65% in the intervention group and 34% in the placebo group (p > 0.05). Conclusion The findings suggest that low-dose oral prednisolone had both a short-term and a longer sustained effect resulting in less knee pain, better physical function, and attenuation of systemic inflammation in older patients with knee OA (Clinical Trials.gov identifier NCT01619163).